Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microe...
Saved in:
Main Authors: | Man Wang (Author), Lijie Zhu (Author), Xiaoxu Yang (Author), Jiahui Li (Author), Yu'e Liu (Author), Ying Tang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
by: Luisa Chocarro de Erauso, et al.
Published: (2020) -
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
by: Mingxia Zhao, et al.
Published: (2019) -
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021) -
PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023) -
Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome
by: Chuan Hu, et al.
Published: (2023)